NewAmsterdam Pharma Company N.V. Deferred Tax Assets, Valuation Allowance
NewAmsterdam Pharma Company N.V. (NAMS) had Deferred Tax Assets, Valuation Allowance of $217.00 million as of 2025-12-31, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-02-18
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $217.00M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $184.63M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $129.84M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $81.38M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $217.00M 10-K · filed 2026-02-18 |
| 2024-12-31 | $184.63M 10-K · filed 2026-02-18 |
| 2023-12-31 | $129.84M 10-K · filed 2025-02-26 |
| 2022-12-31 | $81.38M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |